Edition:
United Kingdom

Formycon AG (FYB.DE)

FYB.DE on Xetra

37.20EUR
18 May 2018
Change (% chg)

€-0.50 (-1.33%)
Prev Close
€37.70
Open
€37.55
Day's High
€38.00
Day's Low
€36.90
Volume
9,893
Avg. Vol
5,342
52-wk High
€39.38
52-wk Low
€28.20

Chart for

About

Formycon AG is a Germany-based company engaged in the development of biological therapeutics. The Company's business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring, as well as the provision of contract services. It is... (more)

Overall

Beta: 1.67
Market Cap(Mil.): €347.03
Shares Outstanding(Mil.): 9.34
Dividend: --
Yield (%): --

Financials

  FYB.DE Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.63 -- --
ROI: -25.14 1.57 14.38
ROE: -26.63 2.43 16.07

BRIEF-Formycon FY Net Loss Of EUR 1.58 Mln

* INCREASED FY TURNOVER BY A GOOD 48 PERCENT COMPARED TO PREVIOUS YEAR TO EURO 29.00 MILLION (2016: 19.53 MILLION)

07 May 2018

BRIEF-Formycon Says Biosimilar Candidate FYB201 Shows Efficacy Comparable To Reference Product In Phase III Study

* BIOSIMILAR CANDIDATE FYB201 SHOWS EFFICACY COMPARABLE TO REFERENCE PRODUCT IN PHASE III STUDY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

02 May 2018

BRIEF-Formycon And Aristo Pharma Are Founding Joint Venture For Development Of FYB202

* PTA-ADHOC: FORMYCON AG: FORMYCON AND ARISTO PHARMA ARE FOUNDING A JOINT VENTURE FOR THE DEVELOPMENT OF FYB202

22 Dec 2017

BRIEF-Formycon 9-month Net Loss at 5.11 Million Euros

* REPORTS OPERATING AND FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2017

27 Nov 2017

Earnings vs. Estimates